IT IS INDICATED FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE -AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT WHO ARE BEING EVALUATED FOR ALZHEIMER'S DISEASE (AD) AND OTHER CAUSES OF COGNITIVE DECLINE.
NEURACEQ IS A RADIOACTIVE DRUG AND SHOULD BE HANDLED WITH APPROPRIATE SAFETY MEASURES TO MINIMIZE RADIATION EXPOSURE DURING ADMINISTRATION . THE RECOMMENDED DOSE OF NEURACEQ IS 300 MBQ (8.1 MCI), MAXIMUM 30 MCG MASS DOSE, ADMINISTERED AS A SINGLE SLOW INTRAVENOUS BOLUS (6 SEC/ML) IN A TOTAL VOLUME OF UP TO 10 ML.